These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18854724)

  • 21. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
    Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
    Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine.
    Entsuah R; Gorman JM
    J Psychiatr Res; 2002; 36(3):111-8. PubMed ID: 11886688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
    Davidson J; Rothbaum BO; Tucker P; Asnis G; Benattia I; Musgnung JJ
    J Clin Psychopharmacol; 2006 Jun; 26(3):259-67. PubMed ID: 16702890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
    Allgulander C; Hackett D; Salinas E
    Br J Psychiatry; 2001 Jul; 179():15-22. PubMed ID: 11435263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
    Levin FR; Mariani J; Brooks DJ; Pavlicova M; Nunes EV; Agosti V; Bisaga A; Sullivan MA; Carpenter KM
    Addiction; 2013 Jun; 108(6):1084-94. PubMed ID: 23297841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release.
    Ferguson JM; Khan A; Mangano R; Entsuah R; Tzanis E
    J Clin Psychiatry; 2007 Jan; 68(1):58-68. PubMed ID: 17284131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
    Gelenberg AJ; Dunner DL; Rothschild AJ; Pedersen R; Dorries KM; Ninan PT
    J Nerv Ment Dis; 2013 Apr; 201(4):266-73. PubMed ID: 23538970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
    Gibbons RD; Hur K; Brown CH; Davis JM; Mann JJ
    Arch Gen Psychiatry; 2012 Jun; 69(6):572-9. PubMed ID: 22393205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder.
    Emslie GJ; Yeung PP; Kunz NR
    CNS Spectr; 2007 Mar; 12(3):223-33. PubMed ID: 17329983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
    Rickels K; Pollack MH; Sheehan DV; Haskins JT
    Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recovery and subsequent recurrence in patients with recurrent major depressive disorder.
    Dunlop BW; Holland P; Bao W; Ninan PT; Keller MB
    J Psychiatr Res; 2012 Jun; 46(6):708-15. PubMed ID: 22475319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB; Thase ME;
    J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.
    Benkert O; Gründer G; Wetzel H; Hackett D
    J Psychiatr Res; 1996; 30(6):441-51. PubMed ID: 9023787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial.
    Richards JS; Bombardier CH; Wilson CS; Chiodo AE; Brooks L; Tate DG; Temkin NR; Barber JK; Heinemann AW; McCullumsmith C; Fann JR
    Arch Phys Med Rehabil; 2015 Apr; 96(4):680-9. PubMed ID: 25527253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Boulton DW; Balch AH; Royzman K; Patel CG; Berman RM; Mallikaarjun S; Reeves RA
    J Psychopharmacol; 2010 Apr; 24(4):537-46. PubMed ID: 18832427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
    Eckert L; Lançon C
    BMC Psychiatry; 2006 Jul; 6():30. PubMed ID: 16867188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.